Small Activating RNAs - a Novel Therapeutic Class of Oligonucleotides
SMi reports: Understanding the principles of RNA activation and possibilities of therapeutic benefit at Oligonucleotide Therapeutics and Delivery Conference 2021.
London, United Kingdom, July 08, 2021 --(PR.com)-- Engage in the latest innovations of oligonucleotide therapeutics with insights into immunochemotherapeutics, ocular indications and Duchenne Muscular Dystrophy. Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery.
Download a copy of your brochure to find out who will be speaking at the upcoming conference in September www.oligonucleotide.co.uk/pr5prcom
Emerging Delivery Solutions
Targeted Delivery of C/EBPa-saRNA by RNA Aptamers
Understanding the principles of RNA activation and possibilities of therapeutic benefit
Harnessing small activating RNAs for the treatment of Pancreatic ductal adenocarcinoma
Evaluating aptamers and appropriate means of targeted delivery
Looking at lessons learnt from using saRNA for oncological purposes
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
Small activating RNAs - a novel therapeutic class of oligonucleotides
Description of saRNA technology to upregulate transcription and broad applicability to a range of therapeutic targets
Generation of a lead candidate saRNA to HNF4a for liver disease
Update on MiNA’s lead saRNA clinical agent MTL-CEBPA – Clinical PD and efficacy
Matthew Catley, Research Director, MiNa Therapeutics Ltd.
The tool-box approach to improve the performance of siRNA-platform technology
Interplay of design and function
Stability and duration of action
Linker design and valency of ligands
Is there room for additional improvements?
Adrien Weingartner, Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics
Clinical development of AsiDNA, a first in class decoy agonist oligonucleotide targeting DNA damage response in tumor cells
Introduction to platON™: proprietary chemistry platform based on a library of decoy agonist oligonucleotides which generates disruptive compounds acting on intracellular DNA-binding targets
Introduction to AsiDNA the leading decoy agonist generated from platON and targeting DNA damage response function
Recent preclinical highlights: AsiDNA abrogates resistance to multiple anti-cancer targeted therapies
Recent clinical development of AsiDNA
Outlining next steps of clinical development
Wael Jdey, Head of Biology, Onxeo S.A.
Register online: www.oligonucleotide.co.uk/pr5prcom
Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience
SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For more details and all delegate enquiries please contact Alia Malick on +44 (0)20 7827 6168.
For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Download a copy of your brochure to find out who will be speaking at the upcoming conference in September www.oligonucleotide.co.uk/pr5prcom
Emerging Delivery Solutions
Targeted Delivery of C/EBPa-saRNA by RNA Aptamers
Understanding the principles of RNA activation and possibilities of therapeutic benefit
Harnessing small activating RNAs for the treatment of Pancreatic ductal adenocarcinoma
Evaluating aptamers and appropriate means of targeted delivery
Looking at lessons learnt from using saRNA for oncological purposes
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
Small activating RNAs - a novel therapeutic class of oligonucleotides
Description of saRNA technology to upregulate transcription and broad applicability to a range of therapeutic targets
Generation of a lead candidate saRNA to HNF4a for liver disease
Update on MiNA’s lead saRNA clinical agent MTL-CEBPA – Clinical PD and efficacy
Matthew Catley, Research Director, MiNa Therapeutics Ltd.
The tool-box approach to improve the performance of siRNA-platform technology
Interplay of design and function
Stability and duration of action
Linker design and valency of ligands
Is there room for additional improvements?
Adrien Weingartner, Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics
Clinical development of AsiDNA, a first in class decoy agonist oligonucleotide targeting DNA damage response in tumor cells
Introduction to platON™: proprietary chemistry platform based on a library of decoy agonist oligonucleotides which generates disruptive compounds acting on intracellular DNA-binding targets
Introduction to AsiDNA the leading decoy agonist generated from platON and targeting DNA damage response function
Recent preclinical highlights: AsiDNA abrogates resistance to multiple anti-cancer targeted therapies
Recent clinical development of AsiDNA
Outlining next steps of clinical development
Wael Jdey, Head of Biology, Onxeo S.A.
Register online: www.oligonucleotide.co.uk/pr5prcom
Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience
SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For more details and all delegate enquiries please contact Alia Malick on +44 (0)20 7827 6168.
For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Jinna Sidhu
020 7827 6088
www.oligonucleotide.co.uk/pr5prcom
Jinna Sidhu
020 7827 6088
www.oligonucleotide.co.uk/pr5prcom
Contact
Categories